| 0560 Serum IL-1b, osteocalcin, CRP levels in rats administered doxycycline, alendronate | ||
|
E. BUDUNELI1, N. BUDUNELI1, S. VARDAR1, L. KARDESLER1, G. ATILLA1, D. LAPPIN2, and D. KINANE3, 1 Ege University School of Dentistry Department of Periodontology, Izmir, Turkey, 2 University of Glasgow, 3 University of Louisville, KY, USA Objectives: Low dose doxycycline has attracted significant interest due to its anti-collagenase effect in prevention of tissue destruction in periodontitis. Recently, biphosphonates have been shown to inhibit alveolar bone resorption. The aim of the present study was to evaluate the effects of doxycycline and a biphosphonate; alendronate on serum levels of interleukin 1-beta (IL-1b), osteocalcin (OC), and C-reactive protein (CRP) in experimental periodontitis. Methods: Experimental periodontitis was induced by repeated injection of Escherichia coli endotoxin (LPS) and forty-four adult male Sprague-Dawley rats were divided into 5 study groups as follows; LPS, doxycycline + LPS, alendronate + LPS, doxycycline + alendronate + LPS, and saline control. Drugs were administered during 7 days-period of experimental study. At the end of the 1-week protocol, serum samples were obtained and analyzed for IL-1b, OC, and CRP levels by ELISA. The jaws were defleshed and alveolar bone loss was analyzed morphometrically. Data were evaluated statistically by parametric tests. Results: Morphometric measurements revealed significantly high bone loss in the LPS, doxycycline + LPS, alendronate + LPS and doxycycline + alendronate + LPS groups in comparison to the saline control group (P<0.05). Serum IL-1b and CRP levels did not exhibit significant differences between the groups. Combined administration of doxycycline and alendronate showed the highest level of OC and the differences between combined drug therapy group and all the other groups were statistically significant (P<0.05). Conclusions: The significantly increased serum OC level which has been previously suggested as a marker of bone formation observed in the combined drug therapy group suggests that combined administration of alendronate and doxycycline might increase bone remodeling and thereby inhibit the progression of alveolar bone resorption. | ||
| Seq #55 - Microbiology/ Immunology and Infection Control 4:00 PM-5:30 PM, Saturday, 28 August 2004 Crowne Plaza Hotel AVSA II | ||
|
Back to the Scientific Program Program
| ||